The state of Iowa has started paying $1,000 per pill for a new drug targeting hepatitis C, but officials don’t plan to buy the medication for every person who carries the virus and qualifies for public health care.
Gilead Sciences Inc. (GILD) is close to a pact with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India,Indonesia, and Pakistan.